A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study
2021
Journal of Thoracic Oncology
Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch ligand expressed in small cell lung cancer (SCLC) tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in patients with extensive stage (ES) SCLC after platinum-based chemotherapy. MERU was a phase 3 randomized, double-blinded, placebo-controlled study. Patients without disease progression following 4 cycles of platinum-based front-line
doi:10.1016/j.jtho.2021.03.012
pmid:33823285
fatcat:rdpm5w3xk5b2pfwnom2kymesdy